1. Home
  2. BBIO vs HOLX Comparison

BBIO vs HOLX Comparison

Compare BBIO & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$76.07

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Logo Hologic Inc.

HOLX

Hologic Inc.

HOLD

Current Price

$76.02

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBIO
HOLX
Founded
2015
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3B
16.9B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
BBIO
HOLX
Price
$76.07
$76.02
Analyst Decision
Strong Buy
Hold
Analyst Count
25
13
Target Price
$86.04
$77.89
AVG Volume (30 Days)
1.5M
11.6M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.79
Revenue
$502,076,000.00
$4,100,500,000.00
Revenue This Year
$89.45
$4.74
Revenue Next Year
$73.78
$5.03
P/E Ratio
N/A
$96.23
Revenue Growth
126.26
1.74
52 Week Low
$31.77
$51.90
52 Week High
$84.94
$76.07

Technical Indicators

Market Signals
Indicator
BBIO
HOLX
Relative Strength Index (RSI) 56.95 69.09
Support Level $70.65 $75.10
Resistance Level $78.20 N/A
Average True Range (ATR) 2.49 0.19
MACD 0.19 0.03
Stochastic Oscillator 60.99 95.19

Price Performance

Historical Comparison
BBIO
HOLX

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About HOLX Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Share on Social Networks: